Skip to content

Treatment of Impaired Glucose Tolerance in Pregnancy

Randomized Controlled, Multicenter Study Evaluating Treatment of Glucose Intolerance in Pregnancy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00625781
Acronym
TIP
Enrollment
72
Registered
2008-02-28
Start date
2008-02-29
Completion date
2013-12-31
Last updated
2016-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Macrosomia, Impaired Glucose Tolerance

Keywords

Gestational diabetes mellitus, Impaired glucose Tolerance, Pregnancy, Fetal macrosomia, Treatment, Perinatal morbidity

Brief summary

The purpose of this study is to evaluate if treatment (insulin or diet) of pregnant women with impaired glucose tolerance (75-g OGTT with a fasting P-gluc \<7.0 mmol/l and 2 h P-gluc \>10.0 and \<12.2 mmol/l) close to normoglycemia reduces children´s birth weight and neonatal morbidity. There will be a focus on treatment according to specific goals and separate follow-up regimes for the children and women post partum.

Interventions

DRUGInsulin aspart and Insulin human (isophane)

Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.

Sponsors

Uppsala-Örebro Regional Research Council
CollaboratorOTHER
Region Örebro County
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women with 75g OGTT result : fasting capillary plasma \<=7.0 mmol/l and/or 2 h value \>= 12.2 mmol/l

Exclusion criteria

* Multiple pregnancy * Pregestational Diabetes

Design outcomes

Primary

MeasureTime frame
Perinatal morbidity and intrauterine growth1 year post partum

Secondary

MeasureTime frame
Children´s future health5 years

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026